Today's Research Reports on Trending Tickers: Keryx Biopharmaceuticals and PTC Therapeutics
NEW YORK, NY / ACCESSWIRE / October 27, 2017 / After posting its largest one day drop in over 7 weeks, the S&P 500 and the Dow rebounded Thursday after a number of major companies reported upbeat earnings. The Dow Jones Industrial Average rallied 0.31 percent to close at 23,400.86, while the S&P 500 Index gained 0.13 percent to close at 2,560.40. The NASDAQ Composite Index was dragged down by biotech and healthcare stocks, falling 0.11 percent to close at 6,556.77. Twitter was one of the largest gainers on the market, with a gain of 18.5 percent, after the company reported earnings that topped expectations and announced that it could turn a profit for the first time ever in the fourth quarter.
"We had some good news from the 'social' sector this morning with Twitter," said JJ Kinahan, chief market strategist at TD Ameritrade. "What's exciting about it is that it shows the resilience of the market."
RDI Initiates Coverage on:
Keryx Biopharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=KERX
PTC Therapeutics Inc.
https://rdinvesting.com/news/?ticker=PTCT
Keryx Biopharmaceuticals Inc.'s stock moved 5.63% lower Thursday, to close the day at $5.53. The stock recorded a trading volume of 3,565,421 shares, which was above its three months average volume of 1,213,380 shares. In the last year, Keryx Biopharmaceuticals Inc.'s shares have traded in a range of 4.11 - 8.38. The share price has gained 34.55% from its 52-week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $7.04 is greater than its 200-day moving average of $6.78. Shares of Keryx Biopharmaceuticals have fallen approximately 5.63 percent year-to-date.
Access RDI's Keryx Biopharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=KERX
On Thursday, shares of PTC Therapeutics Inc. recorded a trading volume of 2,944,382 shares, which was above the three months average volume of 1,069,850 shares. The stock ended the day 6.07% lower at 16.25. The share price has gained 303.23% from its 52-week low with a 52-week trading range of 4.03 - 22.00.The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $18.93 is greater than its 200-day moving average of $16.98. Shares of PTC Therapeutics have gained approximately 48.95 percent year-to-date.
Access RDI's PTC Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=PTCT
Our Actionable Research on Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) and PTC Therapeutics Inc. (NASDAQ: PTCT) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
